Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]

Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med 2020:23 de julio. [Ref.ID 103693]

Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al.. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020:1. [Ref.ID 103691]

Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020:11 de julio. [Ref.ID 103688]

Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hulisiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Hydroxychloroquine in nonhospitalized adults with early COVID-19. A randomized trial. Ann Intern Med 2020:16 de julio. [Ref.ID 103687]

Douros A, Lix LM, Fralick M, Shah BR, Ronksley PE, Tremblay E, Hu N, Alessi-Severini S, Fisher A, Bugden SC, Ernst P, Filion KB, for the Canadian Network of Observational Drug Effect Studies (CNODES) Investigators. Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis A multicenter cohort study. Ann Intern Med 2020:28 de julio. [Ref.ID 103685]

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough P, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, et al. for the mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med 2020:14 de julio. [Ref.ID 103684]

Zaroff JG, Cheetham TC, Palmetto N, Almers L, Quesenberry C, Schneider J, Gatto N, Corley DA. Association of azithromycin use with cardiovascular mortality. JAMA Network Open 2020;3:17 de junio. [Ref.ID 103669]

Anónimo. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration 2020:1. [Ref.ID 103663]

Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of fall eisk-increasing drugs around a fall-related injury in older adults: a systematic review. J Am Geriatr Soc 2020;68:junio. [Ref.ID 103662]

Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, Moslehi JJ, Roden DM, Funck-Brentano C, Salem J-E. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation 2020:22 de mayo. [Ref.ID 103660]

Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]

Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll G, McArthur E, Sood MM. Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med 2020:8 de junio. [Ref.ID 103655]

Blotière P-O, Miranda S, Weill A, Mikaeloff Y, Peyre H, Ramus F, Zureik M, Coste J, Dray-Spira R. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 2020;10:e034829. [Ref.ID 103654]

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]

Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]

Fan-Ngai-Hung I, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al.. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:30 de mayo. [Ref.ID 103649]

Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020;7:abril. [Ref.ID 103647]

Boulware DR, Pullen MF, Bangdiwala AS, Pastik KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, et al.. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med 2020:1. [Ref.ID 103646]

Rydberg DM, Linder M, Malmström RE, Andersen M. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. Eur J Clin Pharmacol 2020;76:867-76. [Ref.ID 103644]